Coronavirus company news summary – Novartis will support CureVac in vaccine manufacturing – GC Pharma will support Moderna’s vaccine distribution in South Korea

5 March 2021 

GC Pharma announced that it will be supporting Moderna and the South Korean Government to distribute 40 million doses of the Covid-19 Vaccine Moderna in the country. The Korea Diseases Control and Prevention Agency had previously announced that it will receive 40 million doses of Moderna’s vaccine starting from the second quarter of 2021.

JCR Pharmaceuticals announced that it will be building a new plant in Japan to expand the production of solutions for Covid-19 vaccines. JCR Pharma, Daiichi Sankyo and other Japanese partners have been collaborating to produce and distribute the Covid-19 vaccine developed by AstraZeneca and University of Oxford. The Japanese Government will be buying 120 million doses of the vaccine.

Curevac and Novartis have signed an initial agreement to manufacture CVnCoV, CureVac’s Covid-19 vaccine candidate. The companies are currently preparing to start the production; technology transfers and test runs are already underway. Following the final agreement, Novartis will be manufacturing the mRNA and bulk drug product  for up to 50 million doses of CVnCoV by the end of 2021, and up to 200 million doses in 2022.

Sign up for our daily news round-up!

Give your business an edge with our leading industry insights.

Sign up